| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
47,934,000 |
| Market
Cap: |
1.44(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.56 - $31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Homology Medicines is a genetic medicines company. Co.'s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors to deliver single administration genetic medicines in vivo either through its gene therapy, Co.'s nuclease-free gene editing modality, or Co.'s gene therapy to express antibodies platform. Co.'s clinical programs include: HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria; as well as HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with PKU.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
343 |
22,368 |
25,768 |
60,242 |
| Total Sell Value |
$8,303 |
$20,843 |
$25,214 |
$73,768 |
| Total People Sold |
2 |
3 |
5 |
7 |
| Total Sell Transactions |
2 |
5 |
8 |
14 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tzianabos Arthur |
President & CEO |
• • – |
2019-10-01 |
4 |
AS |
$17.39 |
$217,468 |
D/D |
(12,500) |
127,505 |
|
- |
|
| Kelly Timothy P |
See Remarks |
• – – |
2019-09-05 |
4 |
AS |
$19.94 |
$23,251 |
D/D |
(1,166) |
0 |
|
- |
|
| Tzianabos Arthur |
President & CEO |
• • – |
2019-09-03 |
4 |
AS |
$18.75 |
$234,320 |
D/D |
(12,500) |
140,005 |
|
- |
|
| Seymour Albert |
Chief Scientific Officer |
• – – |
2019-09-03 |
4 |
AS |
$18.74 |
$174,284 |
D/D |
(9,300) |
191,050 |
|
- |
|
| Smith W Bradford |
CFO, Treasurer & Secretary |
• – – |
2019-09-03 |
4 |
AS |
$18.74 |
$112,419 |
D/D |
(6,000) |
0 |
|
- |
|
| Smith W Bradford |
CFO, Treasurer & Secretary |
• – – |
2019-09-03 |
4 |
OE |
$0.64 |
$3,840 |
D/D |
6,000 |
6,000 |
|
- |
|
| Tzianabos Arthur |
President & CEO |
• • – |
2019-08-01 |
4 |
AS |
$17.37 |
$217,111 |
D/D |
(12,500) |
152,505 |
|
- |
|
| Smith W Bradford |
CFO, Treasurer & Secretary |
• – – |
2019-08-01 |
4 |
AS |
$17.37 |
$104,191 |
D/D |
(6,000) |
0 |
|
- |
|
| Smith W Bradford |
CFO, Treasurer & Secretary |
• – – |
2019-08-01 |
4 |
OE |
$0.64 |
$3,840 |
D/D |
6,000 |
6,000 |
|
- |
|
| Seymour Albert |
Chief Scientific Officer |
• – – |
2019-08-01 |
4 |
AS |
$17.37 |
$161,523 |
D/D |
(9,300) |
200,350 |
|
- |
|
| Rasty Siyamak |
Chief Operating Officer |
• – – |
2019-07-09 |
4 |
AS |
$20.00 |
$160,000 |
D/D |
(8,000) |
222,707 |
|
- |
|
| Smith W Bradford |
CFO, Treasurer & Secretary |
• – – |
2019-07-01 |
4 |
AS |
$19.00 |
$113,971 |
D/D |
(6,000) |
0 |
|
- |
|
| Smith W Bradford |
CFO, Treasurer & Secretary |
• – – |
2019-07-01 |
4 |
OE |
$0.64 |
$3,840 |
D/D |
6,000 |
6,000 |
|
- |
|
| Tzianabos Arthur |
President & CEO |
• • – |
2019-07-01 |
4 |
AS |
$18.98 |
$237,300 |
D/D |
(12,500) |
165,005 |
|
- |
|
| Seymour Albert |
Chief Scientific Officer |
• – – |
2019-07-01 |
4 |
AS |
$18.98 |
$176,539 |
D/D |
(9,300) |
209,650 |
|
- |
|
| Tzianabos Arthur |
President & CEO |
• • – |
2019-06-03 |
4 |
AS |
$19.86 |
$248,263 |
D/D |
(12,500) |
177,505 |
|
- |
|
| Kelly Timothy P |
See Remarks |
• – – |
2019-06-03 |
4 |
AS |
$20.00 |
$25,765 |
D/D |
(1,288) |
0 |
|
- |
|
| Rasty Siyamak |
Chief Operating Officer |
• – – |
2019-06-03 |
4 |
AS |
$20.22 |
$161,778 |
D/D |
(8,000) |
230,707 |
|
- |
|
| Seymour Albert |
Chief Scientific Officer |
• – – |
2019-06-03 |
4 |
AS |
$19.90 |
$185,093 |
D/D |
(9,300) |
218,950 |
|
- |
|
| Smith W Bradford |
CFO, Treasurer & Secretary |
• – – |
2019-06-03 |
4 |
AS |
$19.94 |
$119,664 |
D/D |
(6,000) |
0 |
|
- |
|
| Smith W Bradford |
CFO, Treasurer & Secretary |
• – – |
2019-06-03 |
4 |
OE |
$0.64 |
$3,840 |
D/D |
6,000 |
6,000 |
|
- |
|
| Nelsen Robert |
10% Owner |
– – • |
2019-05-21 |
4 |
D |
$0.00 |
$0 |
D/D |
(300,001) |
5,768,694 |
|
- |
|
| 5am Co-Investors Iv, L.p. |
10% Owner |
– – • |
2019-05-16 |
4 |
S |
$21.47 |
$13,204,050 |
I/I |
(615,000) |
221,435 |
|
- |
|
| Parmar Kush |
Director |
– • • |
2019-05-16 |
4 |
S |
$21.47 |
$13,204,050 |
I/I |
(615,000) |
221,435 |
|
- |
|
| Deerfield Mgmt Hif, L.p. |
*Director by Deputization |
– • • |
2019-04-12 |
4 |
B |
$22.50 |
$11,999,993 |
I/I |
533,333 |
1,158,333 |
2.25 |
- |
|
148 Records found
|
|
Page 5 of 6 |
|
|
0.10 (0.33%) 
